This article first appeared on GuruFocus .
Release Date: November 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Emcure Pharmaceuticals Ltd ( BOM:544210 ) reported a 13% year-on-year revenue growth, achieving its highest quarterly profits of 251 crores, representing a 25% growth.
-
The company has partnered with Novo Nordisk to launch a second brand of semaglutide, targeting the obesity market in India, which has significant potential given the large obese population.
-
The domestic business grew by 10.6% year over year, with strong performance across key segments such as gynecology, cardiology, dermatology, consumer health, and diabetes.
-
International markets showed robust growth, with Europe experiencing a 22% increase and Canada a 17% rise, driven by market share gains and new product launches.
-
Emcure Pharmaceuticals Ltd ( BOM:544210 ) is on track to improve its base margins by 150 basis points this year, supported by operating leverage and productivity gains.
Negative Points
-
The company's net debt increased to 837 crores due to the partial payoff of an additional stake purchase, delaying its goal to become debt-free by the end of FY26.
-
There is uncertainty regarding the potential size of the semaglutide opportunity, as the market is still developing and competitive dynamics are yet to be fully understood.
-
The EBITDA margin has been stable around 19% for several quarters, with limited immediate improvement expected despite ongoing efforts.
-
The company faces challenges in the ARV segment, with lumpiness in sales and a need for strategic adjustments to maintain growth.
-
Emcure Pharmaceuticals Ltd ( BOM:544210 ) is reliant on in-licensing deals for growth, which may impact margins and create dependency on external partnerships.
Q & A Highlights
-
Warning! GuruFocus has detected 3 Warning Signs with BOM:544210.
-
Is BOM:544210 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you provide insights into the potential of the Novo Nordisk semaglutide partnership and its market opportunity in India? A: (Vikas Paper, President Corporate Development Strategy and Finance) The partnership with Novo Nordisk for semaglutide targets a significant market in India, with over 250 million people affected by obesity. While we haven't quantified the opportunity, we believe it has substantial potential. Our early mover advantage and ability to shape the market will help us capture a significant share of this opportunity.
Q: With EBITDA margins stable around 19% for several quarters, do you expect them to remain at this level or increase? A: (Sajuddin Sheikh, CFO) We expect margins to improve by about 150 basis points this year, despite the current 19.3% margin, which includes new in-licensing deals. We are on track to achieve this improvement.
Q: Are you still on track to become debt-free by FY26, given the recent increase in debt? A: (Sajuddin Sheikh, CFO) The increase in debt is due to the acquisition of the remaining stake in Zoventus. We now expect to be debt-free by the end of next year, taking about 18 to 24 months.
Q: How does the Ovitra deal with Novo Nordisk help, considering the patent expiry is anticipated soon? A: (Unidentified_5) The deal allows us to launch the brand ahead of competition, giving us a market-shaping advantage. Our extensive distribution network and field force will help us reach various specialties across India, leveraging Novo's clinical data and experience.
Q: Can you elaborate on the progress and strategy for the biosimilar space? A: (Unidentified_3) We are seeing approvals in emerging markets for tenecteplase and have completed phase 3 trials for rituximab. We plan to submit for regulatory evaluation soon, indicating a strong pipeline and positive growth outlook in the biosimilar space.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
